🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Nicolas Villain / Moved to LinkedIn & BlueSky Simon Mead @PhilAlz Madhav Thambisetty Eric Widera, MD Andrew Lees Robert Howard Jason Cohen Shibley Lon S. Schneider, MD Seb Walsh Michael Schöll @VincentPlanche @StefanoSensi14 Alberto J Espay @KasperKepp Gill Livingston @DrTFromKC @jfballenger @jasonkarlawish James Rupert Fletcher Adam M. Brickman Dr. Jennifer Manly Sarah Ackley, PhD FORTUNE TIME Erin Prater, M.A.², CHES® TIME Financial Times Hannah Kuchler CTAD NIH Alzheimer's Association Howard Gleckman American Geriatrics Society Kathy Liu Richard Merrick Nancy Lundebjerg (she/her/hers) Nathaniel Chin U.S. FDA NICE Raymond Koopmans Maastricht University Kariem Ezzat Dr Ben Underwood NHS England The Observer @iqwig The Labour Party Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis alzres.biomedcentral.com/articles/10.11… via Gábor Csukly et al

Just published! My attempt to make sense of how the autonomic system can shift so dramatically in aging without negatively influencing mood and well-being. nyaspubs.onlinelibrary.wiley.com/doi/10.1111/ny…

Lon S. Schneider, MD @VincentPlanche Madhav Thambisetty Simon Mead Suzanne E Schindler @DrTFromKC Seb Walsh Eric Widera, MD Andrew Lees Robert Howard Jason Cohen Shibley Michael Schöll @StefanoSensi14 Alberto J Espay Nicolas Villain / Moved to LinkedIn & BlueSky @KasperKepp @PhilAlz Gill Livingston @jfballenger @jasonkarlawish James Rupert Fletcher Adam M. Brickman Dr. Jennifer Manly Sarah Ackley, PhD FORTUNE TIME Erin Prater, M.A.², CHES® TIME Financial Times Hannah Kuchler CTAD NIH Alzheimer's Association Howard Gleckman American Geriatrics Society Kathy Liu Richard Merrick Nancy Lundebjerg (she/her/hers) Nathaniel Chin U.S. FDA NICE Raymond Koopmans Maastricht University Kariem Ezzat Dr Ben Underwood NHS England The Observer Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering jamanetwork.com/journals/jama/… via Madhav Thambisetty & Robert Howard

Great initiative and delighted to be part of the winning team 🏆 with Kathy Liu Roeland Heerema & Wanjun Lin. Looking forward to getting started on our project: 'Cognitive & physiological computational markers of neuropsychiatric symptom propensity in #Alzheimer’s disease'

🚨New 𝗣𝗥𝗘𝗣𝗥𝗜𝗡𝗧 🚨 Depression in #Parkinson's disease (PD) is common, disabling & hard to treat. We (Jon Roiser 🟣 Robert Howard anette schrag Yumeya Yamamori) report a key cognitive mechanism associated with PD #depression & novel treatment target: biorxiv.org/content/10.110… Thread -

Adverse childhood events and dementia risk. Good to see a lifecourse approach and interesting to see relatively little mediation from things like smoking, adult depression, or biomarkers. Needs replication in population-representative cohorts academic.oup.com/biomedgerontol…

It's sometimes suggested that dementia risk is higher in people with schizophrenia. Led by Jack Wilson and with Kathy Liu, we reviewed the literature and found no increase in Alzheimer's disease markers in people with schizophrenia. Open access. pubmed.ncbi.nlm.nih.gov/38796179/

Great to have this out 🚨 in Nature Mental Health with Jon Roiser 🟣 anette schrag Robert Howard Should depressive symptom profile guide #Parkinson’s medication 💊 regimen? We found dissociable effects of different PD medications on #depression symptom dimensions. nature.com/articles/s4422…

Really proud of this work, now published in @BrainComms (in MS Word form for now at least) academic.oup.com/braincomms/adv… We consider the ethical conundrums surrounding dementia research, examine the existing legal & ethical guidance, & try to plug some of the gaps in that guidance

Our paper is published in The Lancet Public Health - thanks to co-authors Seb Walsh Gill Livingston Sudha Seshadri, MD and many others. Mapping #dementia #risk factors and prevalence/incidence of dementia over time eur01.safelinks.protection.outlook.com/?url=https%3A%…

Delighted, and grateful to my examiners Oliver Robinson and Alan, my supervisors Robert Howard and Jon Roiser 🟣 and many collaborators/colleagues who have helped me get here.

🚨 New paper, open access in Alzheimer's & Dementia Journals 🚨 Key message: dementia prevention interventions targeted at high-risk groups WON’T produce large reductions in disease incidence, even if 100% effective doi.org/10.1002/alz.14… 1/

🚨 Excited to share our latest paper on assessing the LC-noradrenergic system in early and late-onset Alzheimer's Disease! Hospital Clínic UCSF MAC Global Brain Health Institute Alzheimer's Association Lea T. Grinberg, M.D, Ph.D @Andrea_delvalg Raquel Sánchez-Valle Unitat d’Alzheimer i altres Trastorns Cognitius alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Ash Paul Seb Walsh Simon Mead LogarithmicDis 🦋🇺🇸🇨🇦⛷️🔬🏨 Eric Widera, MD Jason Cohen LTCShop.com @Jeff_Browndyke Paul Jerome Lamont Lon S. Schneider, MD Robert Howard Madhav Thambisetty @KasperKepp Trey Bateman @DanielErsk1ne Shibley Alberto J Espay @PhilAlz Michael Schöll @VincentPlanche @StefanoSensi14 Gill Livingston @DrTFromKC @jfballenger @jasonkarlawish James Rupert Fletcher Adam M. Brickman Dr. Jennifer Manly Sarah Ackley, PhD Erin Prater, M.A.², CHES® Howard Gleckman Kathy Liu Richard Merrick Nancy Lundebjerg (she/her/hers) Nathaniel Chin Emmy Betz, MD, MPH 🇺🇲🩺🔬🤝❤️ Robin Conibere Joanne Ryan Maggie Aime, BSN, RN | Freelance Writer Oskar Hansson Alzheimer's Association Haute Autorité de santé Mayo Clinic David Jones Keck Medicine of USC Big news for the EU! ema.europa.eu/en/medicines/h…

EMA marketing refusal of lecanemab restores some confidence in regulatory processes.

It's today. 27 authors worked hard. We hope you like it, and it has impact on individuals, policy makers, clinicians, and researchers. The Lancet 2024 commission on dementia prevention, intervention, and care. Helen Frankish Naaheed Mukadam Andrew Sommerlad Lon S. Schneider, MD et al.

🚨 New paper 🚨 There is a lot of suffering in our population caused by Alzheimer’s Q: How much of it could be alleviated by new drugs? A: We think, sadly, not much New open access paper in Alzheimer's & Dementia Journals we outline the evidence for our concerns doi.org/10.1002/alz.14… 1/

Very proud to see our new publication with @VincentPlanche in Nat Rev Neurol! We are challenging biological definitions of neurodegenerative diseases. Big thanks to #BernardHanseeuw! Stay tuned for a thread! OA: rdcu.be/dQmvo

Our study explores how sociodemographic factors impact dementia diagnosis rates (DDR) in England. With Naaheed Mukadam Kathy Liu & Jeremy Isaacs tandfonline.com/doi/full/10.10…

Greater memory confidence in people with Alzheimer’s who have delusions. Small numbers as study had to be halted during Covid. Excellent work from Emma McLachlan, @Suzanne__Reeves, Kathy Liu. tandfonline.com/doi/full/10.10…